Pharvaris reported €318 million of cash at June 30, 2026, after a $132.3 million underwritten offering it closed in May. The company says the money extends its runway into 2028, while its quarterly loss reached €47.8 million and its key pivotal trial has yet to report.
Pharvaris agreed to file a resale shelf registration within 30 calendar days for General Atlantic PH B.V., and the investor decides when to sell, how and at what price. The company may postpone the shelf only once in any twelve months, and the filing does not say how many shares the investor holds.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €291.7 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Pharvaris
Has Pharvaris raised money recently?
Our latest story on this, dated Aug 12, 2026: "Pharvaris reports €318 million cash after $132.3 million offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Pharvaris?
Pharvaris N.V. trades under the ticker PHVS on NASDAQ.
Where is Pharvaris listed?
Pharvaris N.V. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9EN; LS:A2QNWS; LSX:A2QNWS.
What is the SEC CIK of Pharvaris?
The SEC Central Index Key (CIK) for Pharvaris N.V. is 1830487. Its filings are on SEC EDGAR.
How many shares does Pharvaris have outstanding?
65,210,590 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-02.
Which country or territory is Pharvaris listed under?
Our directory records Pharvaris N.V. under Netherlands.
What does Pharvaris do?
Our directory classifies Pharvaris N.V. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Pharvaris?
The ISIN recorded for Pharvaris N.V. is NL00150005Y4.
Does aibio.space cover Pharvaris?
aibio.space lists Pharvaris N.V. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Pharvaris incorporated?
SEC records list its state or country of incorporation as P7.
What is the latest Pharvaris (PHVS) stock news?
Our latest story on Pharvaris, dated Aug 12, 2026: "Pharvaris reports €318 million cash after $132.3 million offering". Pharvaris reported €318 million of cash at June 30, 2026, after a $132.3 million underwritten offering it closed in May. The company says the money extends its runway into 2028, while its quarterly loss reached €47.8 million and its key pivotal trial has yet to report. Source.
Is Pharvaris being acquired or merging?
Our latest merger story, dated Sep 8, 2025: "Pharvaris signs registration rights agreement with General Atlantic PH B.V.". Pharvaris agreed to file a resale shelf registration within 30 calendar days for General Atlantic PH B.V., and the investor decides when to sell, how and at what price. The company may postpone the shelf only once in any twelve months, and the filing does not say how many shares the investor holds. Source.
Is Pharvaris a smaller reporting company?
SEC records list Pharvaris N.V.'s filer category as: Large accelerated filer.
Where is Pharvaris headquartered?
SEC records list its business address as J.H. OORTWEG 21, LEIDEN.
When does Pharvaris's fiscal year end?
Pharvaris N.V.'s fiscal year ends on December 31, per SEC records.
Investor discussion: Pharvaris
Members talk about Pharvaris (PHVS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Pharvaris, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PHVS on TradingView.
SEC filings and registration
SEC name
Pharvaris N.V.
CIK
1830487
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
PHVS (Nasdaq)
State or country of incorporation
P7
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
J.H. OORTWEG 21, LEIDEN
Phone
31 (0)71 203 6410
Shares outstanding
65,210,590 as of 2025-12-31 (20-F filed 2026-04-02)
Former names
Pharvaris, B.V.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Pharvaris N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PHVS, recorded under Netherlands. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio